Companies ›Healthcare ›PODD.O

PODD.O — NASDAQ Diversified Medical Equipment & Supplies

Insulet Corp

$169,70

Open in Charts → Attach watcher ⌖

— —

USD

Set alert

Last 30 days

1D5D1M3M6MYTD1Y5YMax

Live price chart loads from the market-data widget.

Mcap

—

P/E

—

EV / Rev

—

Div yield

—

Op margin

12,9 %

ROE

16,3 %

Net margin

9,1 %

Debt / equity

0,63

Beta

—

52w range

—

Volume

3,4k

Day range

$139,02–$144,78

Prev close

$145,76

Open

$144,45

Next earnings

2026-10-28

Ex-dividend

—

TR 1Y

—

About

Insulet Corp develops and commercializes wearable medical devices, primarily the Omnipod insulin pump system, for the treatment of diabetes.

Business. Insulet Corp (PODD.O) is a healthcare services and equipment company listed on the NASDAQ. The firm operates within the medical equipment, supplies, and distribution industry, generating revenue through product sales. Specific details regarding operating segments and geographic mix are not provided.

Classification99 %

SectorHealth Care

Industry groupDiversified Medical Equipment & Supplies

Generated · model-assisted

Sell-side consensus

BUY28 analysts

24 buy3 hold1 sell

Avg 12m price target337,49

Analyst recommendations

28 analysts · consensus Buy

Buy24

Hold3

Sell1

12-month price target

337,49

Consensus of sell-side coverage.

Upcoming events

EarningsQ3 2026 earnings (expected)2026-10-28 · estimated

See all catalysts →

At a glance

Score

—

not yet scored

Valuation

—

valuation pending

Analysts→

Buy

28 analysts · indicative

Ownership→

T. Rowe Price Investment Management, Inc.

largest disclosed fund holder

Profitability→

16,3 %

return on equity

Quality

—

not yet scored

What drives this business

The watch-list the newsroom runs for this company — derived from its sector path, sharpened layer by layer. Not investment advice.

— missing data

News & coverage

No recent newsroom coverage mentioning PODD.

Sector rotation

Sector1D1Mvs mkt

Materials+2,3 %+6,6 %+1,7 %

Communication Services+2,2 %−5,5 %+1,7 %

Energy+0,6 %+3,3 %+0,0 %

Health Care · THIS SECTOR+0,6 %−0,8 %+0,0 %

Information Technology+0,6 %+6,7 %+0,0 %

Consumer Discretionary+0,4 %+7,6 %−0,2 %

Financials−0,4 %−2,7 %−0,9 %

Real Estate−0,7 %+10,9 %−1,3 %

Consumer Staples−0,7 %+2,3 %−1,3 %

Industrials−1,9 %−3,1 %−2,5 %

Utilities−1,9 %+28,2 %−2,5 %

Developing storylines

No tracked sagas currently linked to PODD.O. Browse all sagas →

Analysis

AI analysis

Generated · analysis pipeline · tier hybrid · as of 2026-08-04 ↑ At a glance

Opportunity

— missing data

Upcoming catalysts

Scheduled public events. Informational only — not investment advice.

Company
EarningsQ3 2026 earnings (expected)2026-10-28 · estimated
Macro
Rate decisionBank of England rate decision (press conf.)2026-08-06 · GB
Rate decisionReserve Bank of Australia rate decision (press conf.)2026-08-12 · AU
Rate decisionNorges Bank rate decision (press conf.)2026-08-20 · NO
Rate decisionSveriges Riksbank rate decision (press conf.)2026-09-03 · SE
Rate decisionBank of Canada rate decision (press conf.)2026-09-09 · CA
Rate decisionEuropean Central Bank rate decision (press conf.)2026-09-10 · EU
Macro & political
ElectionSE Swedish Election2026-09-14 · SE
ElectionUS U.S. Midterms2026-11-03 · US
ElectionFR French Legislative2027-06-01 · FR
Congressional trades
CongressTina Smith — Insulet Corporation - Common Stock2026-05-07 · Democrat · MN · Sale · $100,001 - $250,000
CongressTina Smith — Insulet Corporation - Common Stock2026-04-29 · Democrat · MN · Sale · $100,001 - $250,000

Pre-earnings brief

— missing data

Signals & dispatch

peak dispatch · —

Composite-score breakdown

Synthesis

Business

Insulet Corp (PODD.O) is a healthcare services and equipment company listed on the NASDAQ. The firm operates within the medical equipment, supplies, and distribution industry, generating revenue through product sales. Specific details regarding operating segments and geographic mix are not provided.

Classification99 %

SectorHealth Care

Industry groupDiversified Medical Equipment & Supplies

AI synthesis

GENERATED

Insulet Corp maintains a strong liquidity position with $577.4 million in cash and equivalents, but its net cash is negative after subtracting total debt, indicating a potential liquidity risk. The company's debt-to-equity ratio of 0.63 suggests a moderate reliance on debt financing, while its current ratio of 2.81 indicates a solid ability to meet short-term obligations. Free cash flow of $118.1 million and operating cash flow of $569.2 million support its financial flexibility.

Profitability metrics show a return on equity of 16.31% and a return on assets of 7.75%, both exceeding the industry median for medical equipment firms. Gross profit of $1.94 billion and operating income of $349.9 million reflect strong operational efficiency. However, the company's net income of $247.1 million is lower than its operating income, suggesting non-operational expenses or tax impacts.

The company's revenue is concentrated in a single product line, the Omnipod system, which accounts for the majority of its sales. Geographically, the U.S. is the primary market, with limited international exposure. This concentration increases vulnerability to market-specific risks.

Revenue growth has been robust, with a current fiscal year outlook projecting a 12.5% increase in revenue. The next fiscal year is expected to see a 9.8% growth, driven by continued adoption of the Omnipod system and potential new product launches. Historical revenue trends show consistent year-over-year growth, supported by strong demand in the diabetes management market.

Risk factors include a medium liquidity risk due to the negative net cash position and a low dilution risk, as the company has not issued additional shares recently. The risk assessment also notes potential dilution from future capital raises, though the probability is currently low. The company's capital expenditure of -$219.4 million indicates a reduction in capital spending, which may affect long-term growth.

Recent events include a 10-K filing that outlines ongoing product development and regulatory compliance efforts. The company has also issued press releases regarding new partnerships and expanded market access. Analysts have provided a mean price target of $337.49 and a median price target of $350.00, reflecting a generally positive outlook.

Key takeaways

Insulet Corp has a strong liquidity position with $577.4 million in cash and equivalents.
The company's return on equity of 16.31% and return on assets of 7.75% indicate strong profitability.
Revenue is heavily concentrated in the Omnipod system and the U.S. market, increasing vulnerability to market-specific risks.
Analysts project a mean price target of $337.49 and a median price target of $350.00, reflecting a positive outlook.
The company faces a medium liquidity risk due to a negative net cash position after subtracting total debt.

Bull / Bear case

Generated · model-assisted

— missing data

In focus — financials by report

Valuation

Market price

$169,70

Market cap

—

Enterprise valueⓘ

—

P/Eⓘ

—

Non-GAAP P/Eⓘ

—

EV / Revenueⓘ

—

EV / Op incomeⓘ

—

EV / OCFⓘ

—

P / Bⓘ

—

P / Tangible bookⓘ

—

Tangible book

$1.52B

Net cashⓘ

-$371.8M

Current ratioⓘ

2.8

Debt / equityⓘ

0.6

ROAⓘ

7.8%

ROEⓘ

16.3%

Cash conversionⓘ

230.0%

CapEx / revenueⓘ

-8.1%

SBC / revenueⓘ

—

Dilution ratioⓘ

0.0%

Revenue by segment

Business relationships

Business relationships23 disclosed relationships · 2 types · extracted from filings & disclosures

Partners2

Abbott LaboratoriesABT.OPartner95%Source ↗

Dexcom IncDXCM.OPartner95%Source ↗

Subsidiaries21

EX21:03411e1994d2EX21:03411e1994d2Subsidiarie97%

EX21:09bad296523bEX21:09bad296523bSubsidiarie97%

EX21:131630883df2EX21:131630883df2Subsidiarie97%

EX21:23a70cfad4e9EX21:23a70cfad4e9Subsidiarie97%

EX21:285138c9547cEX21:285138c9547cSubsidiarie97%

EX21:344653b6d1fbEX21:344653b6d1fbSubsidiarie97%

EX21:4146bc5f5bacEX21:4146bc5f5bacSubsidiarie97%

EX21:55f23ad09d16EX21:55f23ad09d16Subsidiarie97%

EX21:5e8d9a041115EX21:5e8d9a041115Subsidiarie97%

EX21:6b642c7ebf49EX21:6b642c7ebf49Subsidiarie97%

EX21:724a9639e21bEX21:724a9639e21bSubsidiarie97%

EX21:91eb20eb09fbEX21:91eb20eb09fbSubsidiarie97%

EX21:9ca52b8bdb3eEX21:9ca52b8bdb3eSubsidiarie97%

EX21:b2e8fc3d4aa9EX21:b2e8fc3d4aa9Subsidiarie97%

EX21:be30c45ac841EX21:be30c45ac841Subsidiarie97%

EX21:ce920df3b565EX21:ce920df3b565Subsidiarie97%

EX21:d46ecdef9860EX21:d46ecdef9860Subsidiarie97%

EX21:d6517084c6b0EX21:d6517084c6b0Subsidiarie97%

EX21:e7309fb514f7EX21:e7309fb514f7Subsidiarie97%

EX21:e7b11a887969EX21:e7b11a887969Subsidiarie97%

EX21:f8b279988b4cEX21:f8b279988b4cSubsidiarie97%

Supply chain

Vendors → PODD ↔ Partners → Customers · click any node to drill

2 mentions in 10-K0 from corporate websites0 from news dispatches

Updated 2026-06-24

Peer comparison

Peer comparison8 peers · vs PODD · multiples and returns

ABT—

Abbott Laboratories

$107,13

187,2B USD

P/E

26,3x

— vs self

Div yield

2,4 %

— vs self

ROE

12,5 %

-3,8 vs self

MDT—

Medtronic PLC

$86,19

110,3B USD

P/E

21,4x

— vs self

Div yield

3,4 %

— vs self

ROE

9,7 %

-6,6 vs self

MDLN—

MEDLINE INC.

$40,47

53,2B USD

P/E

202,6x

— vs self

Div yield

—

— vs self

ROE

—

— vs self

SYK—

Stryker Corp

$341,20

131,8B USD

P/E

38,0x

— vs self

Div yield

—

— vs self

ROE

13,5 %

-2,8 vs self

BDX—

Becton Dickinson And Co

$170,21

48,4B USD

P/E

25,6x

— vs self

Div yield

2,8 %

— vs self

ROE

7,0 %

-9,4 vs self

HSIC—

Henry Schein Inc

$88,21

10,1B USD

P/E

80,5x

— vs self

Div yield

—

— vs self

ROE

3,0 %

-13,4 vs self

BAX—

Baxter International Inc

$28,10

14,5B USD

P/E

—

— vs self

Div yield

2,3 %

— vs self

ROE

-15,4 %

-31,7 vs self

SOLV—

SOLVENTUM CORPORATION

$76,83

13,3B USD

P/E

8,6x

— vs self

Div yield

—

— vs self

ROE

30,8 %

+14,5 vs self

Market position

Stress test

— missing data

Predictor forecast

Next quarternear-term

Earnings · next quarterconf 45 %

EPS

Consensus EPS

6,36

Predicted surprise

-0,00

Beat probability

45 %

Analysts

Other metrics

Revenue

—

no estimate

Segment revenue

—

no estimate

Margin

—

no estimate

Segment margin

—

no estimate

as of 2026-05-22 · Earnings Surprise V1

Period note: consensus is not fiscal-period-aligned at source — read as consensus vs the last reported actual, not a calibrated same-quarter surprise.

Full fiscal year~1 year ahead

Full fiscal year · our forecast vs guidance vs consensus

Metric	Our forecast	Guidance	Consensus
EPS	—no estimate	—no estimate	6,36
Revenue	—no estimate	—no estimate	3,3B USD
Operating income	—no estimate	—no estimate	608,9M USD

Full-year consensus mean (period as reported by source) · consensus in USD. Company-level full-year forecast and management guidance are not yet modelled at scale — shown as "no estimate", never inferred.

Probabilistic model output — not investment advice. · generated 2026-08-04

Options

— missing data

Short squeeze

— missing data

Earnings-call key lines

— missing data

Consensus distribution

sell-side coverage

Recommendation distribution28 analysts

Strong buy10

Buy14

Hold3

Sell1

Strong sell0

12-month price target$337,49 · Median $350,00

Low $220,00High $435,00

Operating income · consensus608,9M USD

EPS surprise

−21,8 %

reported vs consensus · miss

Revenue surprise

−18,1 %

reported vs consensus · miss

Estimate revisions

consensus EPS · 26-week trend

— missing data

Sell-side observations

Low$220,00

Mean$337,49

Median$350,00

High$435,00

Spot$169,70

+98.9 %implied to mean12-month sell-side price targets · ▲ spot

Themes

— missing data

ESG

— missing data

Risk factors

Dilution riskLow

Liquidity riskMedium

Filing-based flags

Net cash is negative after subtracting total debt.

Benchmarks vs cohort

Op Margin12,9 %Above median

Net Margin9,1 %Above median

ROE16,3 %Above P75

Capex / Rev-8,1 %Bottom quartile

D/E0,63Below median

Cash Conv2,30Above P75

Corporate actions / M&A

— missing data

FX exposure

— missing data

Comparable transactions

— missing data

Derivatives & instruments

Derivative transactions

Net acquired 31 987 sh6 grants6 insiders

Panos MichaelEVP and CCO · Employee Stock Option (Right to Buy) → Common StockAcquired 7 255 @ $207,04grant · 2026-04-01
Cousin LaetitiaSVP, Reg, Quality & Compliance · Employee Stock Option (Right to Buy) → Common StockAcquired 2 718 @ $245,25grant · 2026-02-24
Singh PremSVP, Global Operations · Employee Stock Option (Right to Buy) → Common StockAcquired 5 570 @ $245,25grant · 2026-02-24
Budden LaurenGroup VP, CAO and Controller · Employee Stock Option (Right to Buy) → Common StockAcquired 1 591 @ $245,25grant · 2026-02-24
Benjamin EricEVP and COO · Employee Stock Option (Right to Buy) → Common StockAcquired 9 946 @ $245,25grant · 2026-02-24
Kapples John W.SVP and General Counsel · Employee Stock Option (Right to Buy) → Common StockAcquired 4 907 @ $245,25grant · 2026-02-24

Actions

Set alert Open in charts

Ask Handelsavisen

— missing data

Data sources

Market data
Market data cache
Issuer disclosures
Public news
Earnings transcripts
Consensus estimates
ESG data

How metrics are computed

Dilution Ratio
(shares_outstanding_diluted - shares_outstanding_basic) / shares_outstanding_basic
Net Cash
cash_and_equivalents + short_term_investments - short_term_debt - long_term_debt
Capex To Revenue
capital_expenditure / revenue
Return On Equity
net_income / total_equity
Debt To Equity
(short_term_debt + long_term_debt) / total_equity
Cash Conversion Ratio
operating_cash_flow / net_income

Source documents

Insulet Corp Market data — financials · 2026-05-29
Insulet Corp Market data — analyst estimates · 2026-05-29
Insulet Corp Market data — ESG · 2026-05-29

Ownership & reference

Top holders

T. Rowe Price Investment Management, Inc.Investment Managers · as of 2026-03-310,26 %$0M
American Century Investment Management, Inc.Investment Managers · as of 2026-03-310,17 %$334M
AQR Capital Management, LLCInvestment Managers · as of 2026-03-310,15 %$335M
Arrowstreet Capital, Limited PartnershipInvestment Managers · as of 2026-03-310,14 %$258M
FMR LLCInstitutional Investor · as of 2026-03-310,04 %$834M
Vanguard Capital Management, LLCInvestment Managers · as of 2025-12-310,04 %$2 473M
Invesco QQQ TrustFunds · as of 2026-03-310,04 %$230M
Geode Capital Management, L.L.C.Investment Managers · as of 2026-03-310,03 %$424M
Goldman Sachs Asset Management, L.P.Investment Managers · as of 2026-03-310,02 %$181M
State Street Investment Management (US)Investment Managers · as of 2026-03-310,02 %$638M
Northern Trust Investments, Inc.Investment Managers · as of 2026-03-310,02 %$146M
Charles Schwab Investment Management, Inc.Investment Managers · as of 2026-03-310,02 %$114M
Nuveen LLCInvestment Managers · as of 2024-12-310,02 %$60M
UBS Financial Services, Inc.Investment Managers · as of 2026-03-310,02 %$94M
Raymond James & Associates, Inc.Brokerage Firms · as of 2026-03-310,02 %$54M
Dimensional Fund Advisors, L.P.Investment Managers · as of 2026-03-310,02 %$77M
JANUS HENDERSON GROUP PLCInstitutional Investor · as of 2026-03-310,02 %$30M
AMERIPRISE FINANCIAL INCInstitutional Investor · as of 2026-03-310,01 %$64M
Bank of New York Mellon CorpInstitutional Investor · as of 2026-03-310,01 %$80M
Morgan Stanley Smith Barney LLCInvestment Managers · as of 2026-03-310,01 %$240M
EATON VANCE MANAGEMENTInstitutional Investor · as of 2022-09-300,01 %$0M
Jennison Associates LLCInvestment Managers · as of 2026-03-310,01 %$15M
Principal Global Investors (Equity)Investment Managers · as of 2026-03-310,01 %$18M
AllianceBernstein L.P.Investment Managers · as of 2026-03-310,01 %$27M
T. Rowe Price Associates, Inc.Investment Managers · as of 2026-03-310,01 %$0M
Victory Capital Management Inc.Investment Managers · as of 2026-03-310,01 %$10M
First Trust Advisors L.P.Investment Managers · as of 2026-03-310,01 %$8M
Wells Fargo AdvisorsBrokerage Firms · as of 2026-03-310,00 %$25M
Capital Research Global InvestorsInvestment Managers · as of 2026-03-310,00 %$35M
Wellington Management Company, LLPInvestment Managers · as of 2026-03-310,00 %$23M
Fisher InvestmentsInvestment Managers · as of 2026-03-310,00 %$12M
JONES FINANCIAL COMPANIES LLLPInstitutional Investor · as of 2026-03-310,00 %$5M
LPL Financial LLCInvestment Managers · as of 2026-03-310,00 %$9M
Franklin Advisers, Inc.Investment Managers · as of 2026-03-310,00 %$7M
PNC Investments LLCInvestment Managers · as of 2026-03-310,00 %$3M
BlackRock Institutional Trust Company, N.A.Investment Managers · as of 2024-06-300,00 %$7M

Leadership

Jim R. HollingsheadPresident, Chief Executive Officer, Director

Insider activity

Net buying2 buys · 1 sellsnet $838K15 insiders · last 365d

STONESIFER TIMOTHY C.Director · Common StockBought 2 790 @ $143,51$400K · 2026-06-03
BORIO LUCIANADirector · Common StockSold 418 @ $143,27$60K · 2026-06-03
WEATHERMAN ELIZABETH HDirector · Common StockBought 3 450 @ $144,20$497K · 2026-06-03
Scannell Timothy JDirector · Common StockOther 1 660 · 2026-05-20
WEATHERMAN ELIZABETH HDirector · Common StockOther 1 660 · 2026-05-20
STONESIFER TIMOTHY C.Director · Common StockOther 1 660 · 2026-05-20
MINOGUE MICHAEL RDirector · Common StockOther 1 660 · 2026-05-20
Huffines Robert LutherDirector · Common StockOther 1 660 · 2026-05-20
Hopfield JessicaDirector · Common StockOther 1 660 · 2026-05-20
Frederick Wayne A.I.Director · Common StockOther 1 660 · 2026-05-20
BORIO LUCIANADirector · Common StockOther 1 660 · 2026-05-20
McEvoy AshleyDirector, President and CEO · Common StockOther 1 411 @ $148,84$210K · 2026-05-13
Panos MichaelEVP and CCO · Common StockOther 2 777 · 2026-04-01
Huffines Robert LutherDirector · Common StockOther 111 @ $209,84$23K · 2026-03-31
Singh PremSVP, Global Operations · Common StockOther 62 @ $246,61$15K · 2026-02-27
Cousin LaetitiaSVP, Reg, Quality & Compliance · Common StockOther 200 @ $246,61$49K · 2026-02-27
Cousin LaetitiaSVP, Reg, Quality & Compliance · Common StockOther 53 @ $246,61$13K · 2026-02-27
Budden LaurenGroup VP, CAO and Controller · Common StockOther 119 @ $246,61$29K · 2026-02-27
Budden LaurenGroup VP, CAO and Controller · Common StockOther 99 @ $246,61$24K · 2026-02-27
Kapples John W.SVP and General Counsel · Common StockOther 411 @ $246,61$101K · 2026-02-27
Kapples John W.SVP and General Counsel · Common StockOther 194 @ $246,61$48K · 2026-02-27
Benjamin EricEVP and COO · Common StockOther 644 @ $246,61$159K · 2026-02-27
Singh PremSVP, Global Operations · Common StockOther 207 @ $246,61$51K · 2026-02-27
Benjamin EricEVP and COO · Common StockOther 268 @ $246,61$66K · 2026-02-27
Benjamin EricEVP and COO · Common StockOther 395 @ $248,12$98K · 2026-02-25

Short positioning

4.6Mshares short-4.3% vs prior

3.61days to cover

72.3%short of daily vol

67fails-to-deliver

as of 2026-07-15 · short-interest report (free)

Index membership

S&P 500United States

Geographic breakdown

— missing data

Listings · one canonical issuer all listings resolve to the canonical

PODD.OCanonical

NASDAQ · USD

Intel & risk

PredictorBeat prob45 %Surprise-0,00Full forecast →

peak dispatch · —

OSINT findings

Dilution riskLow

Liquidity riskMedium

Net cash is negative after subtracting total debt.

Relationship graph

This companySectorPartnersSubsidiaries

Evidence & claims

From filings & derived data

Net margin (FY 2025-12-31): 9.1%Derived (calculated)
Gross margin (FY 2025-12-31): 71.6%Derived (calculated)
Return on equity (FY 2025-12-31): 16.3%Derived (calculated)
Return on assets (FY 2025-12-31): 7.7%Derived (calculated)
Current ratio (FY 2025-12-31): 2.81xDerived (calculated)
Debt-to-equity (FY 2025-12-31): 1.11xDerived (calculated)
Capex (YoY) (2025-12-31 vs 2024-12-31): 53.4%Derived (calculated)
Cost of revenue (YoY) (2025-12-31 vs 2024-12-31): 22.7%Derived (calculated)
EPS (basic) (YoY) (2025-12-31 vs 2024-12-31): -41.2%Derived (calculated)
EPS (diluted) (YoY) (2025-12-31 vs 2024-12-31): -39.8%Derived (calculated)
Gross profit (YoY) (2025-12-31 vs 2024-12-31): 34.2%Derived (calculated)
Net income (YoY) (2025-12-31 vs 2024-12-31): -40.9%Derived (calculated)
Operating cash flow (YoY) (2025-12-31 vs 2024-12-31): 32.3%Derived (calculated)
Operating income (YoY) (2025-12-31 vs 2024-12-31): 53.4%Derived (calculated)
R&D expense (YoY) (2025-12-31 vs 2024-12-31): 37.1%Derived (calculated)
Revenue (YoY) (2025-12-31 vs 2024-12-31): 30.7%Derived (calculated)
Shareholders' equity (YoY) (2025-12-31 vs 2024-12-31): 25.1%Derived (calculated)
Total assets (YoY) (2025-12-31 vs 2024-12-31): 3.3%Derived (calculated)
Total liabilities (YoY) (2025-12-31 vs 2024-12-31): -10.7%Derived (calculated)
Gross profit (annual): USD 1.94BSEC XBRL filing
Total liabilities (annual): USD 1.68BSEC XBRL filing
Revenue (annual): USD 2.71BSEC XBRL filing
Capex (annual): USD 191.6MSEC XBRL filing
Current assets (annual): USD 1.91BSEC XBRL filing

Showing 24 of 59 surfaced claims.

Atomic claims from regulatory filings and derived calculations. Provenance shown as source kind only.

The Thread

Everything we know, in order

2026-10-28EVENTUpcomingQ3 2026 earnings (expected) estimated date

2026-06-30 03:38 UTCEARNINGSUpcomingForecast: earnings_forecast (90d)

2026-06-22 15:57 UTCNEWSAlmedalen week kicks off with focus on party leader speeches → The annual political gathering in Visby begins, with market watchers tracking policy signals from key addresses.

2026-06-20 12:34 UTCANALYSTAnalyst coverage initiated

2026-06-03 00:00 UTCINSIDER3 insider transactions — 2026-06 · net buy $838k

2026-06-03INSIDERSTONESIFER TIMOTHY C. bought 2.8k sh — Director ~$400k

2026-06-03INSIDERBORIO LUCIANA sold 418 sh — Director ~$60k

2026-06-03INSIDERWEATHERMAN ELIZABETH H bought 3.5k sh — Director ~$497k

2026-05-26FILING8-K filing →

2026-05-21FILING8-K filing →

2026-05-20 00:00 UTCINSIDER9 insider transactions — 2026-05 · net sell $210k

2026-05-20INSIDERScannell Timothy J transacted 1.7k sh — Director

2026-05-20INSIDERWEATHERMAN ELIZABETH H transacted 1.7k sh — Director

2026-05-20INSIDERSTONESIFER TIMOTHY C. transacted 1.7k sh — Director

2026-05-20INSIDERMINOGUE MICHAEL R transacted 1.7k sh — Director

2026-05-20INSIDERHuffines Robert Luther transacted 1.7k sh — Director

2026-05-20INSIDERHopfield Jessica transacted 1.7k sh — Director

2026-05-20INSIDERFrederick Wayne A.I. transacted 1.7k sh — Director

2026-05-20INSIDERBORIO LUCIANA transacted 1.7k sh — Director

2026-05-13INSIDERMcEvoy Ashley transacted 1.4k sh — Director, President and CEO ~$210k

2026-05-10CONGRESSTina Smith (senate) sale shares → $100,001 - $250,000

2026-05-06FILING10-Q filing →

2026-05-06FILING8-K filing →

2026-04-29FILING8-K filing →

2026-04-06FILINGDEF 14A filing →

2026-04-01 00:00 UTCINSIDER2 insider transactions — 2026-04 1 derivative

2026-04-01INSIDERPanos Michael transacted 2.8k sh — EVP and CCO

2026-04-01INSIDERPanos Michael acquired 7.3k sh Employee Stock Option (Right to Buy) — EVP and CCO

2026-03-31 00:00 UTCINSIDER1 insider transaction — 2026-03

2026-03-31INSIDERHuffines Robert Luther transacted 111 sh — Director ~$23k

2026-03-12FILING8-K filing →

2026-03-04FILING8-K filing →

2026-02-27 00:00 UTCINSIDER25 insider transactions — 2026-02 · net sell $795k 5 derivative

Showing the 40 most recent of 60 entries.

The entity's full life in the product — typed, chronological, joined across Newspaper, Platform and Data. Our memory, made visible.

Sources filings · IR · transcripts · market data · tier hybrid · as of 2026-08-04 Market data · Issuer disclosures · Public news · Earnings transcripts · Consensus estimates · ESG data Premium coverage

Analyst recommendations

At a glance

What drives this business

News & coverage

Sector rotation

Developing storylines

Analysis

Opportunity

Upcoming catalysts

Pre-earnings brief

Signals & dispatch

Composite-score breakdown

Synthesis

Bull / Bear case

In focus — financials by report

Valuation

Revenue by segment

Market share

Business relationships

Supply chain

Peer comparison

Market position

Stress test

Predictor forecast

Options

Short squeeze

Earnings-call key lines

Consensus distribution

Estimate revisions

Sell-side observations

Themes

ESG

Risk factors

Benchmarks vs cohort

Corporate actions / M&A

FX exposure

Comparable transactions

Derivatives & instruments

Derivative transactions

Actions

Ask Handelsavisen

Ownership & reference

Top holders

Leadership

Insider activity

Short positioning

Geographic breakdown

Intel & risk

Evidence & claims

The Thread